Hims & Hers price target raised to $40 from $24 at Leerink

Leerink raised the firm’s price target on Hims & Hers to $40 from $24 and keeps a Market Perform rating on the shares following the Q4 report. With the semaglutide shortage effectively over, Hims & Hers now should be in a position to drive fundamental price discovery based on its underlying growth more than broad-based speculation, the analyst tells investors in a research note. However, the firm believes the company’s “growth vectors have some ongoing questions, even if the headline outlook calls for ongoing robust growth.”